NewcelX Ltd.

NCEL chart

NewcelX Ltd. news

• NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

  Yahoo Finance · Sep 28, 8:00 AM EDT

• NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

  Yahoo Finance · Jul 31, 9:00 AM EDT

• NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio

  Yahoo Finance · Jul 15, 9:00 AM EDT

• NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

  Yahoo Finance · Jul 8, 9:15 AM EDT

• NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

  Yahoo Finance · Jul 1, 9:30 AM EDT

• NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform

  Yahoo Finance · Jun 15, 8:30 AM EDT

• NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

  Yahoo Finance · May 27, 7:55 AM EDT

• EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

  Yahoo Finance · May 1, 2:00 PM EDT

• Despite NewcelX's Pullback, Insiders Still Gained ₪136k

  Yahoo Finance · May 1, 6:36 AM EDT

• NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

  Yahoo Finance · Apr 30, 8:15 AM EDT

• NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

  Yahoo Finance · Apr 20, 7:37 AM EDT

• NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

  Yahoo Finance · Apr 1, 7:21 AM EDT

NewcelX Ltd. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-09-18
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-08-03
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-31
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-15
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-08
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-07-01
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-30
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-15
• 6-KCURRENT REPORT2026-06-05
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-05-27
• 6-KREPORT OF FOREIGN PRIVATE ISSUER2026-04-30
• 20-FANNUAL REPORT2026-04-29

About NewcelX Ltd.

Ticker

NCEL (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Zurich

Incorporated in

Switzerland

Fiscal year end

December 31

SEC CIK

1783036

Former names

NLS Pharmaceutics Ltd.

Frequently asked questions